Selenium in the Treatment of Arsenic Toxicity and Cancers (SETAC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01442727|
Recruitment Status : Completed
First Posted : September 28, 2011
Last Update Posted : October 7, 2011
Context: Approximately 100 million people throughout the world consume water contaminated with arsenic at levels above carcinogenic thresholds, including 40 million in Bangladesh alone, with up to one-fourth of deaths attributed to arsenic exposure in the worst-affected regions. There are no proven therapies for treating chronic arsenic toxicity or for preventing arsenical cancers. Selenium has been known to counter arsenic toxicity in a variety of animal models. The investigators have recently shown in animals and humans that this effect is mediated by the formation of [(GS)2AsSe]- , the seleno-bis(S-glutathionyl) arsinium ion, which is then rapidly excreted via the hepatobiliary system. Concurrently, two Phase II studies in China and Bangladesh have suggested clinical benefit to selenium supplementation in arsenicosis patients.
Objective: To assess whether daily selenium supplementation counters arsenic toxicity in patients exposed to drinking water arsenic. If proven effective, selenium supplementation might be safely and cost-effectively implemented in the worst-affected localities.
|Condition or disease||Intervention/treatment||Phase|
|Arsenical Melanosis Arsenical Keratosis Arsenical Cancers Arsenicosis Arsenic Exposure Arsenic Toxicity Arsenic Poisoning||Drug: sodium selenite Drug: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||819 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Selenite in the Detoxification of Arsenic and the Prevention of Arsenical Melanosis and Cancers Amongst Bangladeshi Arsenicosis Patients: A 48-week, Randomized, Double-blinded, Placebo-controlled Phase III Trial|
|Study Start Date :||December 2006|
|Actual Primary Completion Date :||April 2009|
|Actual Study Completion Date :||April 2009|
Placebo Comparator: Placebo
Patients who receive control (placebo)
dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
Active Comparator: Selenium
Patients who receive treatment (selenium)
Drug: sodium selenite
200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
- changes in arsenical melanosis [ Time Frame: 0 weeks (baseline), 24 weeks, and 48 weeks (end) ]Arsenical melanosis was recorded in 4 quadrants of each patients' torsos using the Dermlite epiluminescence microscopy system. The images were then scored in a blinded, randomized fashion by a dermatologist.
- changes in blood arsenic levels [ Time Frame: week 0, week 24 and week 48 ]The levels of arsenic in patients' blood was measured to determine whether intervention had a differential effect.
- changes in urinary arsenic levels [ Time Frame: week 0, week 24 and week 48 ]The levels of arsenic in patients' urine was measured to determine whether intervention had a differential effect.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01442727
|SETAC Trial Field Office|
|Kalibari town, Chandpur District, Bangladesh|
|Principal Investigator:||Julian E Spallholz, PhD||Texas Tech University|
|Principal Investigator:||Paul F La Porte, PhD||Pritzker School of Medicine, The University of Chicago|
|Principal Investigator:||Selim Ahmed, MBBS, FCPS||Institute of Child & Mother Health, Dhaka, Bangladesh|